Cardamonin protects against lipopolysaccharide-induced myocardial contractile dysfunction in mice through Nrf2-regulated mechanism

Acta Pharmacol Sin. 2021 Mar;42(3):404-413. doi: 10.1038/s41401-020-0397-3. Epub 2020 Apr 21.

Abstract

In patients with sepsis, lipopolysaccharide (LPS) from the outer membrane of gram-negative bacteria triggers cardiac dysfunction and heart failure, but target therapy for septic cardiomyopathy remains unavailable. In this study we evaluated the beneficial effects of cardamonin (CAR), a flavone existing in Alpinia plant, on endotoxemia-induced cardiac dysfunction and the underlying mechanisms with focus on oxidative stress and apoptosis. Adult mice were exposed to LPS (4 mg/kg, i.p. for 6 h) prior to functional or biochemical assessments. CAR (20 mg/kg, p.o.) was administered to mice immediately prior to LPS challenge. We found that LPS challenge compromised cardiac contractile function, evidenced by compromised fractional shortening, peak shortening, maximal velocity of shortening/relengthening, enlarged LV end systolic diameter and prolonged relengthening in echocardiography, and induced apoptosis, overt oxidative stress (O2- production and reduced antioxidant defense) associated with inflammation, phosphorylation of NF-κB and cytosolic translocation of transcriptional factor Nrf2. These deteriorative effects were greatly attenuated or mitigated by CAR administration. However, H&E and Masson's trichrome staining analysis revealed that neither LPS challenge nor CAR administration significantly affected cardiomyocyte cross-sectional area and interstitial fibrosis. Mouse cardiomyocytes were treated with LPS (4 µg/mL) for 6 h in the absence or presence of CAR (10 μM) in vitro. We found that addition of CAR suppressed LPS-induced defect in cardiomyocyte shortening, which was nullified by the Nrf2 inhibitor ML-385 or the NF-κB activator prostratin. Taken together, our results suggest that CAR administration protects against LPS-induced cardiac contractile abnormality, oxidative stress, apoptosis, and inflammation through Nrf2- and NF-κB-dependent mechanism.

Keywords: apoptosis; cardamonin; cardiac dysfunction; inflammation; lipopolysaccharide; oxidative stress.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cardiomyopathies / chemically induced
  • Cardiomyopathies / complications
  • Cardiomyopathies / pathology
  • Cardiomyopathies / prevention & control*
  • Cardiotonic Agents / therapeutic use*
  • Chalcones / therapeutic use*
  • Female
  • Heart / drug effects
  • Inflammation / chemically induced
  • Inflammation / complications
  • Inflammation / drug therapy
  • Lipopolysaccharides
  • Male
  • Mice
  • Myocardial Contraction / drug effects*
  • Myocardium / pathology
  • Myocytes, Cardiac / drug effects
  • NF-E2-Related Factor 2 / metabolism*
  • NF-kappa B p50 Subunit / metabolism
  • Oxidative Stress / drug effects
  • Signal Transduction / drug effects

Substances

  • Cardiotonic Agents
  • Chalcones
  • Lipopolysaccharides
  • NF-E2-Related Factor 2
  • NF-kappa B p50 Subunit
  • Nfe2l2 protein, mouse
  • Nfkb1 protein, mouse
  • cardamonin